CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ascend Biopharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ascend Biopharmaceuticals Ltd
L 1 159 Dorcas St
Phone: +61 386063488p:+61 386063488 SOUTH MELBOURNE, VIC  3205  Australia Fax: +61 396869866f:+61 396869866
This company is no longer actively traded on any major stock exchange.
Business Summary
Ascend Biopharmaceuticals Ltd is an Australia-based cancer immunotherapy company. The Company is engaged in developing medicines to treat primary, recurrent and metastatic cancers. It applies various different technologies and approaches utilizing viral vectors, and affinity agents that can be conjugated to deliver biologicals and small molecule (immune modulators, kinase inhibitors or chemotherapeutics) payloads. Its product pipeline includes ASN-002, ASN-004 and ASN-008. ASN-002 is an immunotherapy based on a virus engineered to destroy cancer cells when injected directly into the cancer. ASN-002 is based on a genetically modified form of human adenovirus type 5. ASN-004 is an injectable vaccine that delivers cancer antigens to dendritic cells, which activates an immune response to destroy cancer cells. ASN-008 Myeloid Targeting delivers biological and small molecule payloads to Myeloid Dendritic Cells but also Myeloid Derived Suppressor Cells within the tumor microenvironment.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20146/30/2014Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board PeterSmith 49
Chief Financial Officer Kevin G.Hollingsworth 62
Chief Executive Officer, Managing Director, Executive Director ClementLeong
5 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 80,000,000 (As of 6/30/2014)
Stock Exchange: ASX
Fax Number: +61 396869866


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023